Jonas Halfvarson

Prof. Dr. Jonas Halfvarson

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2010 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
AFAndre Franke
Andre Franke
DMDermot P B McGovern
Dermot P B McGovern
JBJeffrey C Barrett
Jeffrey C Barrett
KWKai Wang
Kai Wang
GRGraham L Radford-Smith
Graham L Radford-Smith
MPMiles Parkes
Miles Parkes

6 February 2011 in Nature Genetics
Verified
Journal Article
Open access
PDF file
CACarl A Anderson
Carl A Anderson
GBGabrielle Boucher
Gabrielle Boucher
CLCharlie W Lees
Charlie W Lees
AFAndre Franke
Andre Franke
MDMauro D'Amato
Mauro D'Amato
JRJohn D Rioux
John D Rioux
John Rioux and colleagues report results of a large genome-wide association meta-analysis and follow-up study of ulcerative colitis. They identify 29 new risk loci for this inflammatory disease and show that many risk loci are shared between ulcerative colitis and Crohn's disease. Genome-wide association studies and candidate gene studies in ulcerative colitis have identified 18 susceptibility loci. We conducted a meta-analysis of six ulcerative colitis genome-wide association study datasets, comprising 6,687 cases and 19,718 controls, and followed up the top association signals in 9,628 cases and 12,917 controls. We identified 29 additional risk loci (P < 5 × 10−8), increasing the number of ulcerative colitis–associated loci to 47. After annotating associated regions using GRAIL, expression quantitative trait loci data and correlations with non-synonymous SNPs, we identified many candidate genes that provide potentially important insights into disease pathogenesis, including IL1R2, IL8RA-IL8RB, IL7R, IL12B, DAP, PRDM1, JAK2, IRF5, GNA12 and LSP1. The total number of confirmed inflammatory bowel disease risk loci is now 99, including a minimum of 28 shared association signals between Crohn's disease and ulcerative colitis.

13 February 2017 in Nature Microbiology
Verified
Journal Article
Open access
PDF file
JHJonas Halfvarson
Jonas Halfvarson
CBColin J. Brislawn
Colin J. Brislawn
RLRegina Lamendella
Regina Lamendella
YVYoshiki Vázquez-Baeza
Yoshiki Vázquez-Baeza
WWWilliam A. Walters
William A. Walters
JJJanet K. Jansson
Janet K. Jansson
Inflammatory bowel disease (IBD) is characterized by flares of inflammation with a periodic need for increased medication and sometimes even surgery. The aetiology of IBD is partly attributed to a deregulated immune response to gut microbiome dysbiosis. Cross-sectional studies have revealed microbial signatures for different IBD subtypes, including ulcerative colitis, colonic Crohn's disease and ileal Crohn's disease. Although IBD is dynamic, microbiome studies have primarily focused on single time points or a few individuals. Here, we dissect the long-term dynamic behaviour of the gut microbiome in IBD and differentiate this from normal variation. Microbiomes of IBD subjects fluctuate more than those of healthy individuals, based on deviation from a newly defined healthy plane (HP). Ileal Crohn's disease subjects deviated most from the HP, especially subjects with surgical resection. Intriguingly, the microbiomes of some IBD subjects periodically visited the HP then deviated away from it. Inflammation was not directly correlated with distance to the healthy plane, but there was some correlation between observed dramatic fluctuations in the gut microbiome and intensified medication due to a flare of the disease. These results will help guide therapies that will redirect the gut microbiome towards a healthy state and maintain remission in IBD.

1 December 2010 in Gastroenterology
Verified
Journal Article
Closed access
BWBen P. Willing
Ben P. Willing
JDJohan Dicksved
Johan Dicksved
JHJonas Halfvarson
Jonas Halfvarson
AAAnders F. Andersson
Anders F. Andersson
MLMarianna Lucio
Marianna Lucio
LELars Engstrand
Lars Engstrand

14 March 2016 in Nature Genetics
Verified
Journal Article
Open access
PDF file
T(The International IBD Genetics Consortium (IIBDGC)
The International IBD Genetics Consortium (IIBDGC)
DEDavid Ellinghaus
David Ellinghaus
I(International Genetics of Ankylosing Spondylitis Consortium (IGAS)
International Genetics of Ankylosing Spondylitis Consortium (IGAS)
I(International PSC Study Group (IPSCSG)
International PSC Study Group (IPSCSG)
G(Genetic Analysis of Psoriasis Consortium (GAPC)
Genetic Analysis of Psoriasis Consortium (GAPC)
AFAndre Franke
Andre Franke
David Ellinghaus and colleagues report a combined association analysis of five chronic inflammatory diseases. They identify 27 new associations and highlight disease-specific association patterns at shared susceptibility loci. We simultaneously investigated the genetic landscape of ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis and ulcerative colitis to investigate pleiotropy and the relationship between these clinically related diseases. Using high-density genotype data from more than 86,000 individuals of European ancestry, we identified 244 independent multidisease signals, including 27 new genome-wide significant susceptibility loci and 3 unreported shared risk loci. Complex pleiotropy was supported when contrasting multidisease signals with expression data sets from human, rat and mouse together with epigenetic and expressed enhancer profiles. The comorbidities among the five immune diseases were best explained by biological pleiotropy rather than heterogeneity (a subgroup of cases genetically identical to those with another disease, possibly owing to diagnostic misclassification, molecular subtypes or excessive comorbidity). In particular, the strong comorbidity between primary sclerosing cholangitis and inflammatory bowel disease is likely the result of a unique disease, which is genetically distinct from classical inflammatory bowel disease phenotypes.

9 October 2011 in Nature Genetics
Verified
Journal Article
Open access
PDF file
NINational Institute of Diabetes and Digestive Kidney Diseases Inflammatory Bowel Disease Genetics Consortium (NIDDK IBDGC)
National Institute of Diabetes and Digestive Kidney Diseases Inflammatory Bowel Disease Genetics Consortium (NIDDK IBDGC)
MRManuel A Rivas
Manuel A Rivas
UCUnited Kingdom Inflammatory Bowel Disease Genetics Consortium
United Kingdom Inflammatory Bowel Disease Genetics Consortium
ICInternational Inflammatory Bowel Disease Genetics Consortium
International Inflammatory Bowel Disease Genetics Consortium
MBMélissa Beaudoin
Mélissa Beaudoin
MDMark J Daly
Mark J Daly
Mark Daly, Manuel Rivas and colleagues used next-generation sequencing to study the coding exons of 56 genes from regions previously associated with Crohn's disease. Follow-up analyses in independent case-control series confirmed association of many newly discovered rare variants with disease risk. More than 1,000 susceptibility loci have been identified through genome-wide association studies (GWAS) of common variants; however, the specific genes and full allelic spectrum of causal variants underlying these findings have not yet been defined. Here we used pooled next-generation sequencing to study 56 genes from regions associated with Crohn's disease in 350 cases and 350 controls. Through follow-up genotyping of 70 rare and low-frequency protein-altering variants in nine independent case-control series (16,054 Crohn's disease cases, 12,153 ulcerative colitis cases and 17,575 healthy controls), we identified four additional independent risk factors in NOD2, two additional protective variants in IL23R, a highly significant association with a protective splice variant in CARD9 (P < 1 × 10−16, odds ratio ≈ 0.29) and additional associations with coding variants in IL18RAP, CUL2, C1orf106, PTPN22 and MUC19. We extend the results of successful GWAS by identifying new, rare and probably functional variants that could aid functional experiments and predictive models.